MedTrace Logo

CHF COPD Sip Feed Anabolic Response

NCT02770092 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2025-10-01

No results posted yet for this study

Summary

Weight loss commonly occurs in patients with chronic heart failure (CHF) and chronic obstructive pulmonary disorder (COPD), negatively influencing their quality of life, treatment response and survival. Loss of muscle protein is generally a central component of weight loss in CHF and COPD patients, but patients also have reductions in fat mass and bone density, independent of the severity of the disease state. The purpose of this study is to provide detailed insight in disease related gut function by obtaining information on gut permeability, digestion and absorption of glucose, fat and protein in CHF and COPD patients compared to matched healthy controls. This will provide required information that is necessary to implement new strategies to develop optimal nutritional regimen in CHF and COPD.

Conditions

  • Pulmonary Disease, Chronic Obstructive
  • Congestive Heart Failure

Interventions

OTHER

sip feeding with stable isotope infusion

such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline

Sponsors & Collaborators

Principal Investigators

  • Marielle Engelen · Study Principal Investigator

Study Design

Allocation
NON_RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-02-10
Primary Completion
2018-05-15
Completion
2018-05-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02770092 on ClinicalTrials.gov